Drugs / RAFUTROMBOPAG
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06346925 | Apr → Jul 2024 | primary thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07243418 | Nov 2025 → Nov 2027 expected | breast cancer, thrombocytopenia | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07257809 | Oct 2025 → Sep 2026 overdue | thrombocytopenia | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06838949 | Mar 2025 → Dec 2026 expected | — | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06745219 | Jan → Jun 2025 overdue | cervical cancer, chemotherapy-induced toxicity, thrombocytopenia | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06695741 | Nov 2024 → Feb 2027 expected | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05975996 | Jul 2023 → Dec 2024 overdue | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05660785 | Dec 2022 → Jan 2025 | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 2 | NCT05350956 | Jun 2022 → Jun 2023 | thrombocytopenia | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 2 | NCT05236582 | Mar 2022 → Dec 2024 overdue | thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05252091 | Feb → Aug 2022 | non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06507436 | Jul 2024 → Dec 2026 expected | thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05685420 | Jan 2023 → Jun 2024 | thrombocytopenia due to immune destruction | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05328804 | Jan 2022 → Nov 2023 | autoimmune thrombocytopenia | Yin Jie | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06009965 | Jan 2023 → Jan 2025 | aplastic anemia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07198672 | Oct 2025 → Oct 2027 expected | HER2 positive breast carcinoma | Zhenzhen Liu | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06004791 Comparator | Aug 2023 → Aug 2024 | aplastic anemia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-11 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory CTIT领域全球首个获批的TPO-RA！恒瑞创新药恒曲®新适应症获批，口服给药助力CTIT全程管理 hengrui.com ↗
近日，恒瑞医药收到国家药品监督管理局的通知，批准公司自主研发的1类创新药恒曲 ® （海曲泊帕乙醇胺片）新增适应症： 用于实体瘤化疗为主的抗肿瘤治疗所致血小板减少症（CTIT）成人患者 。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-11 | Jiangsu HengRui Medicine Co., Ltd. | CTIT领域全球首个获批的TPO-RA！恒瑞创新药恒曲®新适应症获批，口服给药助力CTIT全程管理 hengrui.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAFUTROMBOPAG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594401 ↗ |
| Known as | herombopag | “Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months” NCT06695741 ↗ |
| Known as | herombopag olamine | “herombopag olamine tablets” NCT07243418 ↗ |
| Known as | Herombopag Olamine Tablets | “The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in...” NCT05252091 ↗1“Drug: Herombopag Olamine Tablets” NCT06346925 ↗ |
| Known as | Hetrombopag | “We enrolled 54 adults with newly diagnosed NSAA, including 25 with transfusion-dependent NSAA (TD-NSAA) in the prospective, single-arm Phase 2 trial (NCT05660785) to evaluate...” PMID 41489450 ↗ Jan 20261“Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.” PMID 30156363 ↗ Aug 2018 |
| Known as | SHR-8735 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594401 ↗ |
| Action | Activate | “the TPO receptor agonist herombopag” NCT05252091 ↗ |
| Modality | Other / unclassified | “hetrombopag, an oral TPO-RA” PMID 41489450 ↗ Jan 2026 |
| Route | Oral | “with oral herombopag 5 mg/day” NCT05252091 ↗ |
| Target | MPL | “thrombopoietin receptor (TPOR/MPL) agonists” PMID 30156363 ↗ Aug 2018 |